| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13719 | 2012 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020, 2014 | 2661 | 2014 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004, 2015 | 1284 | 2015 |
| Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at … TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ... Journal of Clinical Oncology 33 (28), 3193, 2015 | 1081 | 2015 |
| KIT as a therapeutic target in metastatic melanoma RD Carvajal, CR Antonescu, JD Wolchok, PB Chapman, RA Roman, ... Jama 305 (22), 2327-2334, 2011 | 1008 | 2011 |
| Uveal melanoma MJ Jager, CL Shields, CM Cebulla, MH Abdel-Rahman, HE Grossniklaus, ... Nature reviews Disease primers 6 (1), 24, 2020 | 549 | 2020 |
| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 501 | 2021 |
| Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival GY Ku, J Yuan, DB Page, SEA Schroeder, KS Panageas, RD Carvajal, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 492 | 2010 |
| Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... JAMA oncology 5 (10), 1411-1420, 2019 | 487 | 2019 |
| Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab DF McDermott, CG Drake, M Sznol, TK Choueiri, JD Powderly, DC Smith, ... Journal of clinical oncology 33 (18), 2013, 2015 | 458 | 2015 |
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ... Jama 311 (23), 2397-2405, 2014 | 451 | 2014 |
| Alterations of immune response of non-small cell lung cancer with azacytidine J Wrangle, W Wang, A Koch, H Easwaran, HP Mohammad, F Vendetti, ... Oncotarget 4 (11), 2067, 2013 | 403 | 2013 |
| Metastatic disease from uveal melanoma: treatment options and future prospects RD Carvajal, GK Schwartz, T Tezel, B Marr, JH Francis, PD Nathan British Journal of Ophthalmology 101 (1), 38-44, 2017 | 386 | 2017 |
| Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205 MV Dhodapkar, M Sznol, B Zhao, D Wang, RD Carvajal, ML Keohan, ... Science translational medicine 6 (232), 232ra51-232ra51, 2014 | 372 | 2014 |
| First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study RJ Sullivan, JR Infante, F Janku, DJL Wong, JA Sosman, V Keedy, ... Cancer discovery 8 (2), 184-195, 2018 | 362 | 2018 |
| Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies AP Algazi, KK Tsai, AN Shoushtari, RR Munhoz, Z Eroglu, JM Piulats, ... Cancer 122 (21), 3344-3353, 2016 | 353 | 2016 |
| Uveal melanoma: epidemiology, etiology, and treatment of primary disease BA Krantz, N Dave, KM Komatsubara, BP Marr, RD Carvajal Clinical ophthalmology, 279-289, 2017 | 341 | 2017 |
| Treatment of uveal melanoma: where are we now? J Yang, DK Manson, BP Marr, RD Carvajal Therapeutic advances in medical oncology 10, 1758834018757175, 2018 | 338 | 2018 |
| Aurora kinases: new targets for cancer therapy RD Carvajal, A Tse, GK Schwartz Clinical cancer research 12 (23), 6869-6875, 2006 | 332 | 2006 |
| Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ... Human pathology 46 (3), 357-365, 2015 | 305 | 2015 |
Sandra P. D'AngeloMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
